Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Alice Long

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Diabetes|March 22, 2019
Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D ProgressionTania Habib, S Alice Long, Peter L Samuels, et al.
Diabetologia|October 2, 2023
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumabChantal Mathieu, Alice Wiedeman, Karen Cerosaletti, et al.
Science Translational Medicine|September 16, 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expressionChristian Hundhausen, Alena Roth, Elizabeth Whalen, et al.
Diabetes|October 24, 2024
Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright FutureRoberto Mallone, Emily Sims, Peter Achenbach, et al.
The Journal of Clinical Investigation|September 30, 2025
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetesGabriele Sassi, Pierre Lemaitre, Laia Fernández Calvo, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Journal of Autoimmunity|January 31, 2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patientsMichelle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, et al.
Science Immunology|October 24, 2020
A distinct GM-CSF<sup>+</sup> T helper cell subset requires T-bet to adopt a T<sub>H</sub>1 phenotype and promote neuroinflammationJavad Rasouli, Giacomo Casella, Satoshi Yoshimura, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 12, 2025
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetesLauren E Higdon, Laura A Cooney, Elisavet Serti, et al.
Science Immunology|July 7, 2019
Human CD4<sup>+</sup>CD103<sup>+</sup> cutaneous resident memory T cells are found in the circulation of healthy individualsMaria M Klicznik, Peter A Morawski, Barbara Höllbacher, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Diabetes|March 22, 2019
Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D ProgressionTania Habib, S Alice Long, Peter L Samuels, et al.
Diabetologia|October 2, 2023
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumabChantal Mathieu, Alice Wiedeman, Karen Cerosaletti, et al.
Science Translational Medicine|September 16, 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expressionChristian Hundhausen, Alena Roth, Elizabeth Whalen, et al.
Diabetes|October 24, 2024
Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright FutureRoberto Mallone, Emily Sims, Peter Achenbach, et al.
The Journal of Clinical Investigation|September 30, 2025
Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetesGabriele Sassi, Pierre Lemaitre, Laia Fernández Calvo, et al.
Diabetologia|December 21, 2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosisAna Luisa Perdigoto, Paula Preston-Hurlburt, Pamela Clark, et al.
Journal of Autoimmunity|January 31, 2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patientsMichelle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, et al.
Science Immunology|October 24, 2020
A distinct GM-CSF<sup>+</sup> T helper cell subset requires T-bet to adopt a T<sub>H</sub>1 phenotype and promote neuroinflammationJavad Rasouli, Giacomo Casella, Satoshi Yoshimura, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 12, 2025
Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetesLauren E Higdon, Laura A Cooney, Elisavet Serti, et al.
Science Immunology|July 7, 2019
Human CD4<sup>+</sup>CD103<sup>+</sup> cutaneous resident memory T cells are found in the circulation of healthy individualsMaria M Klicznik, Peter A Morawski, Barbara Höllbacher, et al.
Pageof 8